Teva Concludes Enrollment for Schizophrenia Drug Trial
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
- Latest
- Trending
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
Calliditas Therapeutics reports strong Q4 growth and sets sights on expansion, with TARPEYO sales surging 170% in 2023. CEO optimistic ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.